The dose has gone up, and then up again, and the scale has stopped moving. If the only response from your telehealth prescriber has been another increase, with no explanation of why tirzepatide worked for a while and then stopped, you have probably started to wonder what you are paying for, and what you would pay if you went somewhere else.
This piece answers the money question with dated, published prices and nothing estimated. It sets out the real tirzepatide cost with PCOS for two ways of buying care: a bundled telehealth platform that sells the medication and the clinical support in one monthly price, and GoodLife Health, where a flat membership pays for the clinical care and the pharmacy you choose bills the medication separately. There is one number it will not give you, a single annual total for your situation, because that total depends on your dose, and after a plateau your dose is an open clinical question.
- The membership is $299 a month at every dose and for every medication; a year of it is $3,588.
- Tirzepatide is billed by the pharmacy you choose, at its own price, and GoodLife Health takes nothing on it.
- Lilly's self-pay price for Zepbound vials through LillyDirect was $299 to $449 a month by dose, as published in September 2026.
- Hims published bundled branded Zepbound at $399 a month in August 2026, less per month than our membership plus the drug.
- The difference pays for four lab panels a year and clinicians who look for why you stalled before changing the dose.
- No result, dose or insurance coverage is promised, and not everyone is accepted.
A higher dose, the same scale, and no explanation
Start with what has happened, because the cost question grows out of it. You began tirzepatide, it worked for a while, and then the progress slowed and stopped. You asked what to do, and the answer came back as a higher dose. When that did not move things either, the answer was the same again.
What you did not get is an explanation. Nobody told you why a medication that had been working might stop, what else in your body could be pushing back, or what anyone had looked at before deciding that the next step was more of the same drug. You have PCOS, and as far as you can tell, nobody asked how it fits into the picture.
That leaves you in an awkward place. You pay every month, possibly at a price tied to the medication and the dose, and you cannot tell whether the next increase is the answer or simply the only move your current arrangement offers. Stopping feels like giving up on something that once worked. Staying feels like paying to wait. Switching means learning a new system, a new price structure and new fine print, at the moment you have the least patience for any of it.
The question you came with is deliberately narrow: what will the medication actually cost? It is a good place to start, because cost is the one thing you can check before you commit. It is also harder to answer than it looks, for a reason that has nothing to do with you. On a bundled pricing page, the clinical care and the drug are folded into one figure. Once they are folded together, you cannot see what you pay for the advice and what you pay for the medicine, and you cannot see whether the people giving the advice earn more when the medicine goes up.
So before any prices, it helps to separate the two things you are buying, and to look at why a plateau keeps getting the same answer.
Why a plateau keeps getting the same answer
There are two explanations for a plateau that is met only with dose increases. One is clinical and one is economic, and neither requires anyone to have acted in bad faith.
The clinical one first. A plateau has possible causes, and some of them can be measured. GoodLife Health's honest comparison of GLP-1 telehealth costs names the kinds of things a weight-only program is not built to look at: the thyroid quietly stalling the protocol, the fasting insulin rising years before glucose moves, the hormones driving the weight in the first place. Not every plateau has one of these behind it, and a lab panel does not guarantee an answer. Still, a dose decision made without looking is a guess about which problem you have, and raising the dose treats every plateau as a dose problem.
That is why the care here is labs-first: diagnosis, then treatment, then the long haul. Your PCOS belongs in that picture, and the membership's four cardiometabolic lab panels a year exist so that the picture is measured rather than assumed.
The economic explanation is quieter. The Aligned Medicine guide describes how much of telehealth is built: a membership advertised at $49 to $149, with the margin living in the medication, an upcharge when a patient moves from semaglutide to tirzepatide, and another as the dose titrates up. Under that structure the platform's revenue grows with the prescription, which, in the guide's words, quietly rewards prescribing more and escalating faster. Individual prescribers can act in complete good faith inside a business like that, and the business still has no reason to prefer an answer other than more.
You may not know which kind of arrangement you are in. The pricing page can tell you if you look for one thing: whether the monthly price changes when the medication or the dose changes.
The cost mechanism follows from the same split. When the drug and the care are sold as one bundle, the price is the platform's to set, and the only number you see is the total. When they are unbundled, you see two numbers: a fee for the care, which you can judge on what it includes, and a price for the drug, set by the pharmacy, with the manufacturers' own published self-pay rates as a public reference. The unbundled version shows you everything, which also means it can look more expensive at first glance. For a patient on tirzepatide, at published prices, it does cost more per month, and the next section shows each part with its date so you can see where.
That gap is real, and it is worth being clear about what it pays for before deciding whether it is worth it to you.
What GoodLife Health costs, line by line, and what it does not do
Start with the fee. The GoodLife Health membership is $299 a month, month to month. At sign-up, $598 is charged, and it covers the first two months. If the clinician cannot accept you into care, the $598 is refunded in full; once you are accepted, the first two months are non-refundable. Any medication a pharmacy bills you for follows that pharmacy's own return and refund policy. A year of membership is $3,588.
The fee is the same whatever medication is indicated and whatever the dose, with no molecule upcharge and no dose upcharge. We call this Medication-Neutral Pricing. If your clinician keeps you on tirzepatide, raises the dose, lowers it, or decides something else is indicated, the membership line on your statement stays where it is. The membership fee is generally eligible for HSA or FSA pre-tax dollars.
For that fee you have clinicians licensed in all fifty states, four cardiometabolic lab panels a year, every result in your own hands, asynchronous messaging with the care team, and video visits. For your question, the lab panels matter most, because they are how a plateau gets looked into before a dose gets changed.
Then the medication. It is unbundled: when it is clinically indicated, it is prescribed to the pharmacy you choose, at that pharmacy's own price. GoodLife Health sets nothing, sees nothing and takes nothing on medication. Tirzepatide is sold as Zepbound and as Mounjaro, which the Aligned Medicine guide notes are the same molecule; whether either is indicated for you is the clinician's decision. For a dated reference point on the drug without insurance, Lilly publishes its own self-pay price: through LillyDirect, Zepbound vials were $299 to $449 a month depending on dose, as published in September 2026.
Tirzepatide care, line by line
Published prices with their dates
| Line | GoodLife Health | Hims (branded track) |
|---|---|---|
| How it is sold | $299 membership; medication billed separately by your pharmacy | One bundled monthly price, medication included |
| Care fee | $299 a month, the same at every dose and for every medication | Included in the bundle |
| Tirzepatide | Your pharmacy's price; Zepbound vials $299–$449 a month by dose through LillyDirect (September 2026) | Zepbound $399 a month, bundled (August 2026) |
| Year one | $3,588 in membership plus twelve months of your pharmacy's price | Twelve months of the bundled price for your medication |
| Who sets the drug price | The pharmacy; GoodLife Health takes nothing | The platform, inside the bundle |
Put the two lines side by side and you have the straight answer to your question. GoodLife Health's own cost comparison, at August 2026 prices, puts the all-in figure at $748 a month at injectable maintenance, the top of its range. The bundled alternative costs less per month: Hims published branded Zepbound, bundled with its care, at $399 a month on its pricing page in August 2026. At every published Zepbound price, our membership plus the drug costs more each month than that bundle. You should know that from us before you find it anywhere else.
Insurance can change the drug line. Whether your plan covers tirzepatide is between you, the plan and the pharmacy, and GoodLife Health never promises coverage. Prior authorization, where a plan requires it, is the pharmacy's process; we do not run it, speed it up or claim to win it.
The year-one comparison works the same way. On our side, it is $3,588 in membership plus twelve months of whatever your pharmacy charges for the dose you end up on. On the bundled side, it is twelve months of the bundle at the price published for your medication. This piece does not print a single annual total for either side, because an honest one depends on a dose nobody has chosen yet and on prices that carry dates for a reason. When you have your own pharmacy quote, multiply it by twelve; that figure will be more accurate than any we could estimate for you.
So what does the monthly difference buy? Mostly, it buys measurement. Four panels a year means a plateau is read against your own numbers, every quarter, by clinicians who can see all of them together. It means the decision after a stall can be any of the reasonable ones: hold the dose and look elsewhere, change the dose, change the medication, or treat something the labs turned up. Hormone therapy and thyroid medication are prescribed where indicated, and any FDA-approved medication a clinician judges indicated can be prescribed to your pharmacy.
A stall on tirzepatide is a reason to measure before deciding. Whether the dose rises, holds or falls, or the medication changes, is a clinician's judgment, made after your labs are read.
It also buys a business on the other side of the table with no stake in your dose. The membership is GoodLife Health's revenue; the medication is the pharmacy's. When the fee never moves with the dose, nobody on our side of the table gains anything from turning it up. The Aligned Medicine guide draws the practical consequence: deprescribing becomes thinkable when nothing in the business resists it.
When the fee never moves with the dose, nobody on our side of the table gains anything from turning it up.
What the membership does not do matters just as much. It does not promise that you will lose more weight, or any particular amount. It does not promise that your plateau has a cause a lab panel can find. It does not promise your dose will go down, or that you will stay on tirzepatide at all, because the clinician decides. It does not replace your insurance: it pairs with insurance for catastrophic coverage and replaces the primary-care relationship. And it does not accept everyone. The path is the eligibility check, the intake, the checkout, then a clinician's review.
Weighing it with your own numbers
If you are weighing this, write three figures down. The first is what you pay now, all in, at your current dose. The second is your pharmacy's price for tirzepatide at that dose, or Lilly's published self-pay price as a reference, with its date. The third is the membership at $299 a month. Use your own arithmetic, from your own quotes, rather than anyone's estimate, including ours.
Then ask the question the figures cannot answer for you. If your current plan keeps the monthly total lower and the next step is another increase with no explanation, is the saving worth not knowing why you stalled? Some people will reasonably say yes. If the medication is working well enough and price is what matters most, a bundle may suit you better, and that is a fair decision to make.
Others will decide that the expensive part is paying for a medication without a diagnosis. For them, the membership buys the investigation the dose increases skipped: labs first, clinicians reading them, and a treatment decision made after. At published prices it costs more each month than a bundle. In exchange, it never charges you more because your dose changed, and it earns nothing when you take more medication.
Who this is not for
If the lowest possible monthly figure is what decides it, this membership is the wrong purchase. GoodLife Health sits between the $20,000-a-year concierge practice and the $99-a-month compounded app, and it does not compete with the app on price. It prescribes branded, FDA-approved medication only, and never compounded GLP-1, so it cannot offer you a cheaper copy of tirzepatide. If you want to understand that line, the FDA has published its concerns about unapproved GLP-1 drugs used for weight loss, and the cost comparison guide prices compounded copies in a separate table because they are a different product class.
It is also not for you if what you want is a prescriber who raises the dose on request, a promised result, or a guarantee that insurance will cover your medication. None of those will be offered. It is not a way to stop carrying insurance either, since the membership works alongside it.
It may suit you if you are willing to pay a flat fee for care that starts by measuring, can accept that a clinician may decline to take you on, and want to see the medication bill yourself, line by line, from the pharmacy you chose.
Related Reading
- The True Monthly Cost of GLP-1 Telehealth: An Honest Comparison
- Aligned Medicine: How Zero-Markup Healthcare Actually Works
References
- Zepbound Self Pay Journey Program — LillyDirect vial pricing (Eli Lilly). 2026. zepbound.lilly.com/savings
- FDA's Concerns with Unapproved GLP-1 Drugs Used for Weight Loss (U.S. Food and Drug Administration). 2025. www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss